ea0089c15 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022
Delpassand Ebrahim
, Mohammadi Yazdi Soheil
, Ghantoji Shashank
, Reis Nakasato Antonio
, Denise Strickland Corinne
, Nunez Rodolfo
, Shafie Afshin
, Cork Susan
, Byrne Clare
, Tang Jackson
, Runeckles Kyle
, Patel Jeetvan
Background: Advanced neuroendocrine tumors (NETs) are associated with poor prognoses. A 4-dose regimen of lutetium Lu 177 (177Lu)-DOTATATE has been shown to improve progression-free survival (PFS) and overall survival (OS) in patients with advanced NETs. This is the first United States (US) study to evaluate the effectiveness and safety of additional doses in patients with progressive NETs.Methods: This was a retrospective chart review of 31 a...